G1/S-specific cyclin-D1 (101-109)

G1/S-specific cyclin-D1 (101-109) is a synthetic peptide fragment derived from the cyclin-D1 protein, an essential regulator of cell cycle progression at the G1/S transition. This segment corresponds to amino acids 101 through 109 of cyclin-D1, a region implicated in protein-protein interactions and post-translational modifications that fine-tune cellular proliferation. Due to its defined sequence and relevance to cell cycle control, the peptide serves as a valuable tool for dissecting molecular mechanisms underlying cell division, signal transduction, and oncogenic transformation. Researchers leverage its properties to advance understanding of cyclin-dependent kinase regulation and to model critical aspects of cell cycle checkpoints in vitro.

Cell cycle research: The cyclin-D1 (101-109) peptide is frequently employed in studies focused on the molecular events governing the G1/S phase transition. By mimicking a specific segment of the native protein, it enables detailed investigation into the interactions between cyclin-D1 and its binding partners, such as cyclin-dependent kinases (CDKs) and regulatory inhibitors. Utilizing this fragment, scientists can probe the structural determinants required for complex assembly, phosphorylation events, or competitive inhibition, thereby elucidating mechanisms that modulate cell cycle progression and proliferation.

Protein-protein interaction mapping: Researchers use this peptide as a molecular probe to identify and characterize binding domains within cyclin-D1 and its interacting proteins. Through affinity assays, pull-down experiments, or surface plasmon resonance, the fragment helps delineate contact points essential for functional interactions. Such studies provide insight into the specificity and strength of cyclin-D1 associations, which are critical for understanding how dysregulation of these interactions may contribute to oncogenesis or aberrant cell cycle control.

Antibody production and epitope mapping: The defined sequence of the cyclin-D1 (101-109) peptide makes it an optimal antigen for generating sequence-specific antibodies. These antibodies are valuable for immunodetection techniques such as Western blotting, immunoprecipitation, or immunofluorescence, enabling precise localization and quantification of cyclin-D1 or its modified forms in cell extracts. Additionally, the peptide serves as a standard for epitope mapping, supporting the development and validation of highly specific immunoreagents for research applications.

Phosphorylation and post-translational modification studies: The 101-109 region of cyclin-D1 contains residues that may undergo phosphorylation or other regulatory modifications in vivo. Synthetic access to this peptide allows for in vitro kinase assays, mass spectrometry analysis, or incorporation of site-specific modifications to model endogenous regulatory events. These applications facilitate the investigation of how post-translational modifications influence cyclin-D1 function, stability, and interactions, providing a foundation for understanding cell cycle regulation at the molecular level.

Peptide-based assay development: The cyclin-D1 (101-109) fragment can be incorporated into biochemical assays designed to screen for modulators of cyclin-D1 activity or to monitor the effects of candidate compounds on cell cycle regulatory pathways. By serving as a substrate or competitive inhibitor in enzyme assays, the peptide supports the identification of small molecules or biological agents that target cyclin-D1-dependent processes. Such assay platforms are instrumental in advancing basic research and in the early stages of drug discovery focused on cell cycle control mechanisms.

1. Immune responses to peptides containing homocitrulline or citrulline in the DR4-transgenic mouse model of rheumatoid arthritis

2. The effect of sex on immune responses to a homocitrullinated peptide in the DR4-transgenic mouse model of Rheumatoid Arthritis

3. Peptides as Active Ingredients: A Challenge for Cosmeceutical Industry

4. C-peptide and its C-terminal fragments improve erythrocyte deformability in type 1 diabetes patients

5. Cell-based adhesion assays for isolation of snake venom’s integrin antagonists